Alto Neuroscience Inc. (ANRO)
Alto Neuroscience Statistics
Share Statistics
Alto Neuroscience has 27.07M shares outstanding. The number of shares has increased by 0.7% in one year.
| Shares Outstanding | 27.07M |
| Shares Change (YoY) | 0.7% |
| Shares Change (QoQ) | 0.38% |
| Owned by Institutions (%) | 82.31% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 2,337 |
| FTD / Avg. Volume | 0.72% |
Short Selling Information
The latest short interest is 3.27M, so 12.08% of the outstanding shares have been sold short.
| Short Interest | 3.27M |
| Short % of Shares Out | 12.08% |
| Short % of Float | 15.32% |
| Short Ratio (days to cover) | 8.21 |
Valuation Ratios
The PE ratio is -1.69 and the forward PE ratio is -0.82. Alto Neuroscience's PEG ratio is -0.02.
| PE Ratio | -1.69 |
| Forward PE | -0.82 |
| PS Ratio | 0 |
| Forward PS | 1.7 |
| PB Ratio | 0.69 |
| P/FCF Ratio | -2.1 |
| PEG Ratio | -0.02 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Alto Neuroscience.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 16.92, with a Debt / Equity ratio of 0.11.
| Current Ratio | 16.92 |
| Quick Ratio | 16.92 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | -0.25 |
| Debt / FCF | -0.34 |
| Interest Coverage | 49.9 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-808,302.63 |
| Employee Count | 76 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -83.06% in the last 52 weeks. The beta is 2.16, so Alto Neuroscience's price volatility has been higher than the market average.
| Beta | 2.16 |
| 52-Week Price Change | -83.06% |
| 50-Day Moving Average | 2.63 |
| 200-Day Moving Average | 6.6 |
| Relative Strength Index (RSI) | 52.02 |
| Average Volume (20 Days) | 324,814 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -68.61M |
| Net Income | -61.43M |
| EBITDA | -68.61M |
| EBIT | -62.81M |
| Earnings Per Share (EPS) | -2.5 |
Balance Sheet
The company has 168.23M in cash and 16.94M in debt, giving a net cash position of 151.28M.
| Cash & Cash Equivalents | 168.23M |
| Total Debt | 16.94M |
| Net Cash | 151.28M |
| Retained Earnings | -138.4M |
| Total Assets | 177.54M |
| Working Capital | 159.33M |
Cash Flow
In the last 12 months, operating cash flow was -47.42M and capital expenditures -2.08M, giving a free cash flow of -49.5M.
| Operating Cash Flow | -47.42M |
| Capital Expenditures | -2.08M |
| Free Cash Flow | -49.5M |
| FCF Per Share | -2.01 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ANRO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ANRO is $10, which is 309.8% higher than the current price. The consensus rating is "Buy".
| Price Target | $10 |
| Price Target Difference | 309.8% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Scores
| Altman Z-Score | 0.37 |
| Piotroski F-Score | 4 |